Alkem enters into licensing agreement with BioTherapeutics
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Subscribe To Our Newsletter & Stay Updated